Combination therapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced lung cancer (stage IIIB/IIIC/IV or extensive-stage small cell) that cannot be treated with surgery or standard chemoradiation.
- You must have at least one tumor that can be measured on scans.
- You must be able to care for yourself (ECOG score 0 or 1).
- You must not have active brain metastases, serious heart or lung problems, or recent bleeding or clotting issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a combination of SYS6010 and an immunotherapy drug (anti-PD-(L)-1) given after surgery to prevent non-small cell lung cancer from coming back. It's for people whose cancer was removed but didn't shrink much with prior treatment before surgery.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
This trial tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer that does not have an EGFR mutation and has stopped responding to previous treatments. The goal is to see which treatment works better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.